Melanotan-1 — Research Summary
Linear melanocortin peptide analog studied for skin pigmentation, photoprotectio
Melanotan-1
An evidence summary of published preclinical research on Melanotan-1. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.
Molecular Data
Compound Overview
Melanotan-1 (also known as afamelanotide) is a synthetic linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH) developed at the University of Arizona. It is a 13-amino acid peptide that activates melanocortin-1 receptors (MC1R) on melanocytes to stimulate eumelanin production.
Reported Mechanism (Preclinical)
Melanotan-1 binds to MC1R on melanocytes, activating adenylyl cyclase and increasing intracellular cAMP levels. This triggers the MITF transcription factor cascade, upregulating tyrosinase and other melanogenic enzymes that convert tyrosine to eumelanin. Eumelanin (the brown/black pigment) is studied in UV photoprotection research. Unlike Melanotan-II, Melanotan-1 is selective for MC1R with minimal activity at MC3R, MC4R, and MC5R.
Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.
Key Research Highlights
- Selective MC1R agonism with minimal MC3R/MC4R/MC5R activity reported in receptor-binding assays
- Upregulated tyrosinase and eumelanin synthesis in cultured melanocyte models
- Studied alongside MC1R signaling in UV-induced DNA-damage research models
Published References
-
Protective effect of sunless tanning with afamelanotide against UV-induced DNA damage
Exp Dermatol, 2006 -
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo
JAMA Dermatol, 2015 -
MC1R signaling and its protective role against UV-induced skin cancer
Pigment Cell Melanoma Res, 2018
Available for Research
Lab-tested, third-party COA published, ships from the U.S.
View Product · Melanotan-1 View COA Library